Device Cardiac Resynchronization Therapy - Crt

Amplia Mri Quad Crt-D Surescan

Payments companies reported to CMS as associated with Amplia Mri Quad Crt-D Surescan. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$30Kassociated payments (2023-2025)
128clinicians with associated payments
1company reporting

By year

2023 $15K
2024 $5,560
2025 $9,030

Payments reported as associated with Amplia Mri Quad Crt-D Surescan, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Clinical Cardiac Electrophysiology $14K
Cardiovascular Disease $7,927
Interventional Cardiology $2,630
Internal Medicine $893
Thoracic Surgery (Cardiothoracic Vascular Surgery) $474
Nurse Practitioner $346

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Amplia Mri Quad Crt-D Surescan

These are the largest totals companies reported as associated with Amplia Mri Quad Crt-D Surescan. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Robert Canby Austin, TX Clinical Cardiac Electrophysiology $2,006.33
Daniel Cooper Saint Louis, MO Clinical Cardiac Electrophysiology $1,594.97
Omid Yousefian Santa Barbara, CA Cardiovascular Disease $1,388.47
Steven Song Fremont, CA Cardiovascular Disease $1,145.35
Andrea Tordini Tampa, FL Clinical Cardiac Electrophysiology $1,133.63
Susan Kim Chicago, IL Clinical Cardiac Electrophysiology $1,100.44
Brian Seeck Washington, MO Cardiovascular Disease $1,093.48
Alexey Sergeev Morgantown, WV Clinical Cardiac Electrophysiology $1,018.34
Richard Pham Cleveland, OH $946.64
Joseph Lightsey Augusta, GA Clinical Cardiac Electrophysiology $934.78

Prescribed Amplia Mri Quad Crt-D Surescan?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.